dnl343
Small moleculeexperimental
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
1
Phase 4
0
Earliest trial started Feb 29, 2020 (NCT04268784)
Timeline
Indications
Mechanism of action
inhibitor - EIF2b
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06281158 | Phase 1 | Mar 1, 2024 | Denali Therapeutics Inc. |
| NCT05842941 | Phase 2/Phase 3 (Phase 3) | May 24, 2023 | Denali Therapeutics Inc., Harvard University |
| NCT05006352 | Phase 1 | Aug 11, 2021 | Denali Therapeutics Inc. |
| NCT04581772 | Phase 1 | Dec 31, 2020 | Denali Therapeutics Inc. |
| NCT04268784 | Phase 1 | Feb 29, 2020 | Denali Therapeutics Inc. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Denali Therapeutics Inc. | For profit | 5 | 4 | 2 | 2020 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2023 |
2 organizations
Page 1 / 1